Three completed cohorts reporting findings in non-small cell lung cancer, breast, and metastatic colorectal cancer from the American Society of Clinical Oncology Inc.'s Targeted Agent and Profiling Utilization Registry study were presented in poster sessions during the American Association for Cancer Research Annual Meeting 2019.
Stand Up To Cancer is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors, such as osteosarcoma and mesothelioma.
Imvax Inc. announced positive results from an ongoing phase Ib clinical trial that demonstrate treatment with IGV-001, the company's novel autologous tumor cell vaccine, outperformed standard of care with prolonged overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme.
Astellas Pharma Inc. announced results from the phase III ADMIRAL clinical trial comparing Xospata (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
A study at MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma. Findings from the phase II trial were presented by study co-lead Nathan Fowler, associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.
The north-eastern region of the Islamic Republic of Iran has some of the highest rates of esophageal cancer anywhere in the world. New results from an international prospective study of 50,000 individuals, recently published online in the journal Gastroenterology, provide evidence on how the combined effects of six main risk factors are responsible for the high rates of esophageal cancer in this region.
In melanoma patients, taking over-the-counter probiotic supplements was associated with a 70% lower chance of response to cancer immunotherapy treatment with anti-PD-1 checkpoint inhibitors, according to a preliminary study from the Parker Institute for Cancer Immunotherapy and MD Anderson Cancer Center. The results were presented at the American Association for Cancer Research 2019 Annual Meeting in Atlanta.
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2- mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented at the AACR Annual Meeting 2019.
Amy Abernethy, FDA principal deputy commissioner, was appointed the agency's acting chief information officer and lead the Office of Information Management and Technology in addition to her other duties.
Zihai Li was named director of the Institute for Immuno-Oncology at Ohio State University Comprehensive Cancer Center-James Cancer Hospital.
